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A B S T R A C T
Purpose
The purpose of this trial was to evaluate the effect of a Web-based, self-report assessment and
educational intervention on symptom distress during cancer therapy.
Patients and Methods
A total of 752 ambulatory adult participants were randomly assigned to symptom/quality-of-life
(SxQOL) screening at four time points (control) versus screening, targeted education, communi-
cation coaching, and the opportunity to track/graph SxQOL over time (intervention). A summary of
the participant-reported data was delivered to clinicians at each time point in both groups. All
participants used the assessment before a new therapeutic regimen, at 3 to 6 weeks and 6 to 8
weeks later, completing the final assessment at the end of therapy. Change in Symptom Distress
Scale–15 (SDS-15) score from pretreatment to end of study was compared using analysis of
covariance and regression analysis adjusting for selected variables.
Results
We detected a significant difference between study groups in mean SDS-15 score change from
baseline to end of study: 1.27 (standard deviation [SD], 6.7) in the control group (higher distress)
versus0.04 (SD, 5.8) in the intervention group (lower distress). SDS-15 score was reduced by an
estimated 1.21 (95% CI, 0.23 to 2.20; P  .02) in the intervention group. Baseline SDS-15 score
(P  .001) and clinical service (P  .01) were predictive. Multivariable analyses suggested an
interaction between age and study group (P  .06); in subset analysis, the benefit of intervention
was strongest in those age  50 years (P  .002).
Conclusion
Web-based self-care support and communication coaching added to SxQOL screening reduced
symptom distress in a multicenter sample of participants with various diagnoses during and after
active cancer treatment. Participants age  50 years, in particular, may have benefited from
the intervention.
J Clin Oncol 32:199-205. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Including self-reported cancer symptoms and
quality-of-life (SxQOL) concerns in cancer care has
increased over the last three decades for several rea-
sons: focusonpatient-reportedoutcomes (PROs) in
clinical trials for product development, the need to
adjust therapeutic doses based on toxicities, the
number of patients with complexmultimodal ther-
apies, the emphasis on patient-centered care, and
the shift from inpatient to ambulatory and home
administrationof therapy. Simultaneously, resource
constraints have reduced face-to-face patient/clini-
cian time. Web-based SxQOL assessment and sup-
port of patients during active cancer treatment offer
the potential to efficiently and conveniently collect
PROs for both research and clinical use as well as to
improve patient outcomes. In addition to our own
prior randomized trial,1 pilot studies2 and random-
ized trials in non-US settings3-5 have shown SxQOL
clinical screening to be feasible and clinically
beneficial with regard to communication and
patient outcomes.
In the first Electronic Self-Report Assessment–
Cancer (ESRA-C) randomized clinical trial,1
we demonstrated the feasibility, acceptability,
and efficacy of computerized SxQOL screening at
a large comprehensive cancer center in Seattle,
Washington, increasing the frequency of patient/
clinician communication about problematic is-
sues as measured in audiorecorded clinic visits.
We did not collect SxQOL outcome data past the
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visit targeted for intervention and could not evaluate impact of the
screening plus clinician summary on later SxQOL outcomes.
Moreover, we found that even when clinicians received summaries
of patient-reported SXQOL, the most frequently addressed issues
were those either regulated by certification bodies (eg, pain) or
likely to be affected by supportive care medications previously
ordered by the clinician (eg, nausea with antiemetics). These issues
were discussed whether or not the patient had problems, whereas
other issues reported as problematic by the patient (eg, insomnia)
often were left unaddressed. We designed a new trial in which the
clinician summary intervention would be delivered for all partici-
pants, and the new intervention would support patients directly
through self-care strategies and communication of priority issues.
The new intervention offered tailored education, communication
coaching, and SxQOL tracking and was accessible from home at
times convenient to patient users.
PATIENTS AND METHODS
Study Design and Participants
ESRA-C IIwas aprospective, randomized clinical trial designed todeter-
mine the effect of a patient education and coaching intervention added to a
self-report assessmentwith clinician summary on SxQOLoutcomes through-
out a new therapeutic regimen for patientswith various cancer diagnoses. The
quality health outcomes model6 informed our trial design. The authors pos-
ited that system and provider variables could influence the outcome of prac-
tically every intervention delivered. Thus, we enhanced the usual care system
with self-report and a clinician summary and measured many potentially
influential aspects (eg, use of intervention at home or clinic) and face-to-face
communication patterns between patients and providers.7
The study was conducted in ambulatory care of two comprehensive
cancer centers between April 2009 and June 2011 with approval by the insti-
tutional review boards of the Fred Hutchinson Cancer Research Center/Uni-
versity of Washington Cancer Consortium and the Dana-Farber Cancer
Assessed for eligibility
(N = 2,234)
Random assignment
(n = 779)
Allocated to intervention (n = 389)
  Received allocated intervention (n = 374)
  Did not receive allocated intervention (n = 15)
    (did not meet inclusion criteria)
Allocated to control (n = 390)
  Received allocated intervention (n = 378)
  Did not receive allocated intervention (n = 12)
    (did not meet inclusion criteria)
)303 = n( rednopseR
)84 = n( rednopsernoN
)4 = n( desaeceD  
)11 = n( desufeR  
)81 = n( lli ooT  
)51= n( tcatnoc ot elbanU  
)123 = n( rednopseR
)62 = n( rednopsernoN
)2 = n( desaeceD  
)6 = n( desufeR  
)7 = n( lli ooT  
)9 = n( tcatnoc ot elbanU  
  No response to ESRA-C (n = 2)
)992 = n( rednopseR
)52 = n( rednopsernoN
)1 = n( desaeceD
)5 = n( desufeR
)1 = n( lli ooT
)41 = n( tcatnoc ot elbanU
No response to ESRA-C (n = 4)
)913 = n( rednopseR
)53 = n( rednopsernoN
)6 = n( desaeceD
)01 = n( desufeR
)2 = n( lli ooT
)31 = n( tcatnoc ot elbanU
No response to ESRA-C (n = 4)
)342 = n( rednopseR
)61 = n( rednopsernoN
)2 = n( desaeceD  
)3 = n( desufeR  
)1 = n( lli ooT  
  Unable to contact (n = 10)
)252 = n( rednopseR
)03 = n( rednopsernoN
)3 = n( desaeceD  
)5 = n( desufeR  
)3 = n( lli ooT  
  Unable to contact (n = 19)
)554,1 = n( dedulcxE
Did not meet inclusion criteria/could (n = 576)
  not complete T1 before treatment
  start
Declined to participate (n = 879)
2 emiT2 emiT
3 emiT3 emiT
4 emiT4 emiT
Fig 1. CONSORT diagram; study exclu-
sion and inclusion, random assignment,
and follow-up information. Electronic Self-
Report Assessment–Cancer (ESRA-C).
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Institute. Eligible patients had a diagnosis of cancer, were ambulatory and
age  18 years, were starting a new therapeutic regimen, and spoke/read
English (Fig 1). Patientswere recruited from the transplantation service in one
cancer center (Seattle, WA) and from medical and radiation oncology in the
other (Boston,MA). Baseline ESRA-C assessments were offered to all patients
meeting eligibility criteria, accessible from a home computer or touchscreen
notebook in clinicwaiting areas. Patientswere queriedon screen for interest in
a study about the computer program. Research staff obtained written in-
formed consent, which included use of the baseline questionnaire (T1) as
research data. The initial response rate was lower than expected; after 14
months, we changed to in-person recruitment.
Participants self-identified as home or clinic users, and within these
strata, the computer application randomly allocated them at a ratio of one to
one in blocks of four to the intervention or control group. Participants in the
intervention group were given a brief tutorial on using the self-administered
intervention; those without home computers could use the intervention in
clinic at any time. Home users received a 1-week follow-up telephone call to
answer questions and remind them of the available intervention features.
Participants completed a second assessment (T2) approximately 3 to 6
weeks after starting treatment when symptoms were likely to be prevalent. A
third assessment (T3) was scheduled 2 weeks later to assess participants’
response toT2problemSxQOL issues. The final assessment (T4)was planned
2 to 4weeks after treatment ended.During the study, thedecisionwasmade to
administer a T4 assessment to those participants who would continue to
receive treatment indefinitely (eg, palliative treatment, maintenance therapy)
at the next restaging visit.
Intervention and Control Conditions
Intervention-group participants used the new intervention to self-assess
SxQOL not only when prompted at each study time point but also ad lib
between visits. After each self-report, the program delivered three messages
regarding SxQOL issues reported at a predetermined threshold (Appendix
Table A1, online only): first, why and how often this issue typically occurs;
second,whatcanbedone; andthird,howto talk toyourclinical teamabout the
issue. Participants were coached to verbalize specifics tailored for each SxQOL
issue toproviders:first, howoftenandwhen the issueoccurs; second, intensity;
Pain Frequency Nausea Intensity Fatigue
Appetite Bowel Troubles Concentration
Sleeping Troubles Appearance Impact on Sexuality
Cough Fear and Worry Breathing
Fever and Chills
Symptom Distress
3/17 7/23 11/28 4/5 8/11 12/17 4/23 8/29
Worse 4
3
2
1
Better 0
Shaded area may indicate a
higher level of symptom distress
What do I tell my clinical team? Be sure to talk with your 
clinical team during your next visit. You should tell your 
clinicians that you have concerns about fatigue and ask if 
there’s something they can suggest to help. It’s important 
that they know you’re bothered about the effects of the 
treatment. We suggest saying something like this:
“My fatigue is a ___ out of 10 (fill in the blank to describe 
your fatigue level where 0 is no fatigue at all and 10 is the 
worst fatigue you can imagine).  For example __________ 
(describe how the fatigue has affected you or interefered 
with your daily activities).  It’s gotten __________ (better or 
worse) since I saw you last. What do you recommend 
to deal with this?”
Teaching Tips Share
Fatigue
Impact on Sexuality
Pain Intensity
Social and Family
Sleeping Troubles
Breathing
Please rate today’s pain or discomfort on a scale of 0-10 by touching or 
clicking one of the numbered buttons below, where 0 means no pain or 
discomfort and 10 is the worst you could imagine.
0 1 2 3 4 5 6 7 8 9 10
You have reported a high level of pain. Please remember that your answers on this 
computer questionnaire are not meant to replace talking to your health care provider. 
We strongly recommend that you talk to your health care provider today about your 
pain. Even if you do not have an appointment scheduled, we recommend that you 
contact your provider today after you complete this report.
1. Patients answer questions via touch screen interface;
    inline warnings alert patients to seek help when needed.
2. Patients choose two most bothersome SQI.
3. Patients are coached to describe SQI.4. Patients can view all trends at a glance or explore 
    one or more in detail.
Fig 2. Illustration of the Electronic Self-Report Assessment–Cancer II patient-centered intervention. SQI, self-reported cancer symptom and quality-of-life issue.
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third, alleviating or aggravating factors; and fourth, request help. Additional
features alerted patients to call providers right away when levels of symptom
distress, depression, and/orpainwere severe orwhenany suicidal ideationwas
reported in between clinic visits. An illustration of the intervention compo-
nents is provided in Figure 2.
Participants could visualize graphed responses over time for each of 24
SxQOL issues, whether at threshold levels or not, and annotate the results
using a journal feature. All intervention participants could explore self-care
strategies and coaching for any SxQOL issue at any time.
Control-group participants completed the same SxQOL assessments,
butonlyat eachstudy timepoint; summary reportsweredelivered toclinicians
as in the interventiongroup.Researchstaff verballynotified theproviderofany
severe levels of depression and/or pain reported at the time of the clinic visit.
Both groups were provided the same patient education as was typically avail-
able in each clinic.
Measures
The ESRA-C questionnaires screen for cancer-related SxQOL issues:
symptom distress, quality of life, depression, peripheral neuropathy, skin
changes, and pain. The assessment has been described previously.1 The pri-
mary outcome for the study was symptom distress, a construct that addresses
multiple symptoms common across cancer diagnoses. For this trial, we used
theoriginal 13-itemSymptomDistress Scale (SDS)8plus two items(impacton
sexual activity and interest, fever/chills) to form the SDS-15. Each item had a
5-point response option from 1 (no or minimal distress) to 5 (maximal
distress). Item scoreswere summed for a total, unweighted scale score ranging
from 15 to 75. Internal consistency of the SDS-15 was calculated as 0.83 at
baseline and 0.86 at the end of study.
Statistical Analyses
Ourprimaryendpointwas change inSDS-15 total score frombaseline to
theend-of-study timepoint (T4); if apatienthadfinished treatmentbeforeT3,
T4 was not administered, and the T3 score was used. With a target of 315
patients in each arm (630 patients total), the study was designed to detect an
effect size of 0.26 with 90% power, at the two-sided significance level of .05
with a t test. Given the attrition rate of 11% in the previous study,1 the target
enrollment sample originally was 702. Because the observed attrition rate
during this trial was approximately 20%, the study was amended to a maxi-
mum sample size of 796.
Baseline patient characteristics were summarizedwith descriptive statis-
tics. Attrition was assumed missing at random and validated by checking
baseline characteristics for participants with and without complete data.
Change in SDS-15 total score from baseline to end of study was calcu-
lated for eachpatient and comparedbetween study groupsusing an analysis of
covariance (ANCOVA) approach, linear regression adjusting for baseline
SDS-15 score. All randomly assigned eligible patients with outcome data were
included according to the intent-to-treat principle. As a process check, we
calculated intervention access frequencies in server logs. Nonparametric
smoothing techniques were used to explore the impact of baseline SDS-15
score and age on score change. Covariates previously identified as influencing
symptom distress (age, clinical service, working status, and baseline SDS-15
score) were assessed with univariable analysis and then adjusted inmultivari-
able analysis to improve the precision for estimating the intervention effect.
Emotional functioning (European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire–Core 30 [EORTC QLQ-C30]) and
depression (Patient Health Questionnaire–Depression [PHQ9]) scores at
baseline were also explored as covariates, but because the two variables were
highly correlated with SDS-15 at baseline (data not shown), they were re-
moved from the analysis. Possible two-way interactions were checked in the
multivariable model. Type III P values were used to assess overall significance
in all models. Because an age and study group interaction was suggested from
the smoothing graph and multivariable regression model (P  .06), subset
analyses were conducted within two age groups.
Participants lost to attrition before T4 were excluded from the analysis
according to protocol. However, 37 were still undergoing therapy and had
SDS-15 scores available at T3. Thus, we added these 37 to the analysis sample
for a secondary sensitivity analysis (n 618) using the last available SDS-15
Table 1. Demographic and Baseline Clinical Characteristics of Eligible
Participants (N  752)
Characteristic
Control
(n  378)
Treatment
(n  374)
No. % No. %
Age, years
Median 59 56
Range 19-88 22-86
Age group, years
 50 90 24 126 34
 50 288 76 248 66
Sex
Male 204 54 185 50
Female 174 46 189 50
Ethnicity/race
Minority 27 7 33 9
Missing 43 11 37 10
Working status
Working† 222 59 222 60
Not working 113 30 123 33
Missing 43 11 29 8
Clinical service
Medical oncology 210 56 211 56
Radiation oncology 117 31 125 33
Hematopoietic stem-cell transplantation 51 14 38 10
Cancer diagnosis
Breast 97 26 109 30
Colorectal 31 8 34 9
Pancreatic 10 3 4 1
Esophageal 7 2 11 3
Gastric 5 1 3 1
GI, other‡ 13 3 16 4
Head and neck 26 7 24 6
Prostate 60 16 62 17
Bladder 13 3 10 3
Renal cell 4 1 9 2
Testicular 11 3 9 2
Sarcoma 15 4 19 5
Leukemia 22 6 14 4
Myeloma 17 4 13 4
Non-Hodgkin lymphoma 21 6 23 6
Hodgkin lymphoma 11 3 6 2
Other§ 10 3 7 2
Unknown primary 5 1 1 0.3
Group stage (solid tumors)
0 (DCIS) 9 3 3 0.6
I 58 19 52 16
II 71 23 86 27
III 51 17 66 21
IV 111 36 101 32
Missing 7 2 10 3
Abbreviation: DCIS, ductal carcinoma in situ.
P  .04.
†Working includes: full time, part time, working at home, on medical leave,
or any one of these categories plus retired.
‡Adenocarcinoma (appendix, small bowel, ampullary gland, duodenum,
gallbladder), Bismuth IV Klatskin tumor, carcinoid tumor (small bowel), chol-
angiocarcinoma, GI stromal tumor, mucinous neoplasm (appendix), and pan-
creatic neuroendocrine.
§Carcinoid tumor (unknown primary origin, bronchial), Merkel cell carcinoma,
retroperitoneal germ cell tumor, and Wilms tumor.
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score (T3) to test the impact of attrition on outcome. All analyses were con-
ducted using SAS (version 9.2; SAS Institute, Cary, NC) and R software
(http://www.r-project.org); all statistical tests were two sided at a significance
level of .05.
RESULTS
We enrolled and randomly assigned 779 participants (Fig 1).
Twenty-seven enrolled participants were found to be ineligible after
randomassignment. Table 1 lists demographic and clinical character-
istics of the eligible study sample (n 752). There were no significant
differences in age, sex, race/ethnicity, disease stage, or attrition among
participants recruited on screen or by personal contact (data not
shown). The study groups were well balanced except for age; partici-
pants were younger in the intervention group compared with the
control group (P .04).A largemajority (86%)ofpatients enrolled as
homeusers.Completionrates forend-of-studyoutcomeswere similar
for both arms (control, 77.2%; intervention, 77.3%).
A total of 581 eligible participants (17% attrition rate) who com-
pletedthestudyperprotocolcomprisedthetargetanalyticsample,includ-
ingthosewhoansweredatT4andthosewhocompletedcancer treatment
beforeT3. Participantsmissing full SDS-15 scores at baseline (n 44) or
end of study (n 22) were removed from the main analysis, for a final
sampleof 523. Participantswithmissingdatawereolder (P .0002) and
fromminority backgrounds (P .06). Table 2 summarizes the available
sample sizes and SDS-15 scores for each timepoint.
Participants randomly assigned to the intervention arm had
lower symptomdistress;mean change in SDS-15 scorewas 1.27 (stan-
dard deviation [SD], 6.7) in the control group (higher distress) and
0.04 (SD, 5.8) in the intervention group (lower distress). In our
primary ANCOVA analysis, SDS-15 score was reduced by an esti-
mated 1.21 (95% CI, 0.23 to 2.20; P .02) in the intervention group
versus the control group. For the 289 intervention participants,
ESRA-Cserver logs revealedamedianaccess rateof four (range, twoto
four)at study timepoints andofone(range, zero toeight) at voluntary
times. One outlier (66 voluntary access sessions) was removed from
the calculation.
Study group and age were significantly associated with SDS-15
score change in univariable analyses (Appendix Table A2, online
only). Inmultivariable analysis of SDS-15 score change, the interven-
tion effect remained significant (95% CI, 2.07 to 0.03; P  .04;
Appendix Table A2). In addition, clinical service and baseline SDS-15
score were significantly predictive. Score changes indicating lower
symptom distress were evident for the treatment group and partici-
pants treated with radiation therapies. Visual inspection of results
from the smoothing techniques (Fig 3) suggested that the higher the
baseline symptomdistress (SDS-15 score), thegreater the reduction in
SDS-15 score by end of study, although those with very low baseline
values had increased symptom distress by end of study.
The only interaction suggested bymultivariable analysis was be-
tween age and study group (P .06); this was exploredwith smooth-
ing techniques. The results shown in Figure 4 suggested there was
minimal difference in SDS-15 score change between control and in-
tervention groups for younger participants (age 50 years), whereas
the difference was evident among older participants (age 50 years).
For the group of older participants, SDS-15 score seemed to increase
from baseline to end of study in the control group, whereas it re-
mained stable in the intervention group (Fig 4).
We performed a subset multivariable regression analysis, using
the 50 years of age mark suggested by the smoothing curve, and a
statistically significant intervention effect (Table 3) was identified
among participants age  50 years; a reduction of an average 1.93
points in SDS-15 score change was seen in the intervention group
comparedwith thecontrolgroup(95%CI,3.16 to0.70;P .002).
There was no significant intervention effect detected among partici-
pants age  50 years (P  .40). Clinical service was significantly
associated with SDS-15 score change only among older participants
(P  .01), and working status was significant only in the younger
group (P .04).
Sensitivity analyses revealed a difference by treatment group in
SDS-15 score change between baseline and end of study (estimate,
Table 2. Means and SDs of SDS-15 Scores and Sample Sizes at Each Time Point (n  581)
Group
T1 (baseline) T2 T3/4 (end of study)
No. Mean SD No. Mean SD No. Mean SD
Control (n  292) 268 24.1 6.8 269 26.6 7.5 282 25.4 7.9
Treatment (n  289) 269 24.3 6.7 264 26.6 7.7 277 24.2 6.7
Abbreviations: SD, standard deviation; SDS-15, Symptom Distress Scale–15.
Baseline SDS-15
20 30 40 50
Control
Intervention
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Fig 3. Effect of baseline Symptom Distress Scale–15 (SDS-15) score on SDS-15
score change between baseline and end of study.
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1.21; 95% CI, 0.23 to 2.20; P  .02), similar to the difference in the
primary analysis. The intervention effect remained significantly (P
.04) associated with SDS-15 score change in multivariable analysis,
and it significantly interacted with age (P .05; Appendix Table A3,
online only); the intervention effect was significant (P .001) among
older but not younger participants (P  .20; Appendix Table A4,
online only).
DISCUSSION
Use of the ESRA-C patient-centered intervention resulted in lower
symptomdistress when comparedwith symptomdistress under con-
trol conditions over the course of ambulatory cancer treatment in a
sample of adult patients of various cancer diagnoses and stages at two
comprehensive cancer centers in the United States. ESRA-C access
frequencies in the intervention-group participants indicated interest
in remote access between clinic visits. These findings extend the po-
tential efficacy of the ESRA-C program, with the addition of the
patient-centered intervention (ESRA-C II) to the clinician-centered
intervention of the ESRA-C I trial (control condition in ESRA-C II).
Our organizing framework, the health outcomes model,6 has
been confirmed in part with our results. Patient variables, age in
particular, influenced theeffectof the interventiononoutcomes. Inan
earlier analysis, we found that patient self-appraisal of change in qual-
ity of life was influential with regard to quality-of-life outcomes.9
Other randomized controlled trial results are similar; however,
these trials involvedprimarily samplesoutsideof theUnitedStates and
were limited to single institutions or selecteddiagnoses.3-5 TheoneUS
randomized trial10 was a nurse-led, telephone-based intervention
based on pain and depression algorithms delivered to patients with
cancer from16urban and rural care sites in Indiana. The intervention
resulted in significantly lowerpainanddepression inpatientswhohad
reportedmoderate to severe pain and/or depression at enrollment.
Although the statistically significant difference in change be-
tween study groups was small, it was realized over the likely positive
impact of the summary clinician report for both groups. What is the
meaning of an SDS-15 score change difference of 1.21 for the entire
sample or of 1.93 (adjusted model) in those age 50 years? A differ-
ence of 1 to 2 points could reflect the difference between intensity or
distress fromone symptomora1-point changeon two separate items.
Reducing symptomdistress, even at a smallmagnitude, with an inter-
vention that engages patients in self-care and adds no time to a clinic
visit is patient-centered care in action.11
Ruland et al4 inNorway reported a small significant difference in
global symptom distress measure by the Memorial Symptom Assess-
mentScale–ShortForm12whentestingaWeb-basedsymptomreport-
ing and support system in thosewithbreast orprostate cancer.Aswith
our findings, variability in stage and diagnosis likely had an impact on
effect size. There are many descriptive studies using the SDS, but few
randomized studies published in which SDS score was the primary
outcome and was significantly different between groups.
There are several plausible explanations for finding the stronger
intervention effect in older participants. Middle-age and older adults
mayhaveneededmore support to access reliable and focused self-care
information on the Internet than younger participants. Furthermore,
olderparticipantsmayhavebenefited fromcommunicationcoaching,
whereas the younger participants in both groupsmay have beenmore
inclined to articulate SxQOL and ask more questions, as has been
found in other communication research.13,14
Table 3. Multivariable Regression Analysis of SDS-15 Score Change by Age (n  523)
Variable
Age  50 Years (n  162) Age  50 Years (n  361)
Estimate 95% CI P Estimate 95% CI P
Study group (intervention v control) 0.87 0.94 to 2.67 .4 1.93 3.16 to 0.70 .002
Age 0.05 0.07 to 0.17 .4 0.01 0.10 to 0.077 .8
Service .3 .01
HSCT v radiation oncology 0.44 2.88 to 3.75 .8 0.21 2.72 to 2.30 .9
Medical oncology v radiation oncology 1.57 0.51 to 3.65 .1 1.85 0.55 to 3.14 .005
Work status (not working v other) 2.26 0.08 to 4.43 .04 0.87 0.55 to 2.28 .2
SDS-15 baseline 0.27 0.40 to 0.14  .001 0.43 0.53 to 0.34  .001
Abbreviations: HSCT, hematopoietic stem-cell transplantation; SDS-15, Symptom Distress Scale–15.
Continuous variable.
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Fig 4. Effect of age on Symptom Distress Scale–15 (SDS-15) score change
between baseline and end of study.
Berry et al
204 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 192.148.225.201 on October 29, 2017 from 192.148.225.201
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Generalizing our results outside of a comprehensive cancer cen-
ter is questionable; the results are likely to be associatedmorewith the
demographics of patients who seek care at such a center than the
setting itself. A majority of our participants had and used Internet
access at home or work. Patients who refused participationmay have
lacked familiarity with technology. Although only a small percent of
the sample hadmissing data on the SDS, older andminority individ-
uals were more likely to skip items.
Racial and ethnic diversity rates in our mainly New England
sample were lower than the Massachusetts population, in which ap-
proximately19%reportminority raceorethnicity.15Our studyresults
cannotbegeneralized tonon–English speakingpatients.Our interpre-
tation of the effect of clinical service is limited by that the overlap of
that variablewith accrual site.Differenceswe attributed to servicemay
have resulted from other clinical or patient population characteristics
of the accruing sites.
Screening for psychosocial problems in patients with cancer has
been included in the American College of Surgeons and Commission
on Cancer 2012 Cancer Program standards.16 The ESRA-C system
addresses such screening needs, common cancer-specific physical
symptoms and adverse effects, and self-care needs of patients. Com-
bining screening, communication coaching, and automated, tailored
self-care information adds value to the required screening anddoes so
with minimal staff involvement. ESRA-C may facilitate integrated
organizational processes that link identified needs to coordinated,
patient-centered treatment and tracking of clinical outcomes.17 Be-
cause ESRA-C provides patients with the opportunity to self-identify
priority SxQOL issues among items scored at the moderate to high
distress level, two important types of information can be used clini-
cally: the current level of symptomatology and the patient’s self-
appraisal of theproblem. In the future, ESRA-Ccanbe adapted for the
specific needs of a clinic patient population and revised for deploy-
ment and use on a variety of remote devices.
Future analyses and studies could examine the mechanisms by
which communication coaching reduces symptom distress and the
individual characteristics predisposing patients to benefit from the
intervention, as well as dosing effects. Other outcomes relevant to
symptomatology should be evaluated, such as emergency room visits
and clinic resource use.
In conclusion, adding self-care support and educational mes-
sages to the ESRA-C assessment program reduced symptom distress
in amulticenter sample of participants with various diagnoses during
and after active cancer treatment. Participants age  50 years, in
particular, may have benefited from the intervention.
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Appendix
Table A1. SxQOL Issues Assessed During ESRA-C Study
SxQOL Issue
Instrument Used for
Assessment Score Used for Intervention
Nausea frequency SDS (original 13-item scale) Each item was scored 1 (lowest) to 5 (highest) in severity; scores  3 were color
coded as problematicNausea intensity
Appetite
Insomnia
Pain frequency
Pain intensity
Fatigue
Bowel troubles
Concentration
Appearance
Breathing
Fear and worry
Cough
Impact on sexuality Additional items in SDS-15
Fever and chills
Pain intensity Numeric 0-10 rating scale Scores  5 were color coded as problematic
Depression PRIME-MD PHQ9† Scores of 10 (moderate depression) or higher were color coded as problematic
Physical functioning EORTC QLQ-C30 (version 3)‡ Each scale (two to five items) was scored 0 (worst) to 100 (best); scores  50
were color coded as problematicEmotional functioning
Social functioning
Cognitive functioning
Role functioning
(work and leisure)
Sensory neuropathy EORTC QLQ-CIPN20§ Each scale (three to eight items) was scored 0 (best) to 100 (worst); scores  50
were color coded as problematicMotor neuropathy
Autonomic neuropathy
Skin problems Adapted One item rated severity of skin problems from 1 (not present) to 6 (very severe);
scores of 3 (mild) or higher were color coded as problematic
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ESRA-C, Electronic Self-Report Assessment–Cancer; PHQ9, Patient Health
Questionnaire–Depression; PRIME-MD, Primary Care Evaluation of Mental Disorders; QLQ-C30, Quality of Life Questionnaire–Core 30; QLQ-CIPN20, Quality of Life
Questionnaire–Chemotherapy-Induced Peripheral Neuropathy; SDS, Symptom Distress Scale; SxQOL, cancer symptoms and quality of life.
McCorkle R: Semin Oncol Nurs 3:248-256, 1987.
†Kroenke K, et al: J Gen Intern Med 16:606-613, 2001.
‡Aaronson NK, et al: J Natl Cancer Inst 85:365-376, 1993.
§Postma TJ, et al: Eur J Cancer 41:1135-1139, 2005.
Ryan JL, et al: Br J Cancer 97:14-21, 2007.
Table A2. Univariable and Multivariable Regression Analyses of SDS-15 Score Change (n  523)
Variable
Univariable Analysis Multivariable Analysis
Estimate 95% CI P Estimate 95% CI P
Study group (intervention v control) 1.30 2.36 to 0.24 .016 1.05 2.07 to 0.03 .04
Age 0.04 0.0003 to 0.086 .05 0.03 0.01 to 0.08 .12
Service .12 .01
HSCT v radiation oncology 0.71 2.84 to 1.42 .51 0.30 1.71 to 2.30 .77
Medical oncology v radiation oncology 0.94 0.19 to 2.07 .10 1.60 0.49 to 2.71 .005
Work status (not working v other) 0.37 0.83 to 1.58 .54 1.03 0.13 to 2.19 .08
SDS-15 baseline 0.35 0.42 to 0.27  .001 0.37 0.45 to 0.30  .001
Abbreviations: HSCT, hematopoietic stem-cell transplantation; SDS-15, Symptom Distress Scale–15.
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Table A3. Univariable and Multivariable Regression Analyses of SDS-15 Score Change in Sensitivity Analysis (n  555)
Variable
Univariable Analysis Multivariable Analysis
Estimate 95% CI P Estimate 95% CI P
Study group (intervention v control) 1.14 2.19 to 0.08 .04 1.04 2.05 to 0.03 .04
Age 0.03 0.01 to 0.07 .13 0.02 0.02 to 0.07 .28
Service .01
HSCT v radiation oncology 1.25 3.30 to 0.80 .23 0.07 2.00 to 1.86 .94
Medical oncology v radiation oncology 1.24 0.11 to 2.37 .03 1.79 0.68 to 2.90 .002
Work status (not working v other) 0.43 0.75 to 1.62 .48 1.19 0.048 to 2.34 .04
SDS-15 baseline 0.33 0.41 to 0.26  .001 0.37 0.44 to 0.30  .001
Abbreviations: HSCT, hematopoietic stem-cell transplantation; SDS-15, Symptom Distress Scale–15.
Table A4. Multivariable Regression Analysis of SDS-15 Score Change by Age in Sensitivity Analysis (n  555)
Variable
Age  50 Years (n  177) Age  50 Years (n  378)
Estimate 95% CI P Estimate 95% CI P
Study group (intervention v control) 1.14 0.60 to 2.88 .20 2.01 3.25 to 0.78 .001
Age 0.02 0.09 to 0.14 .68 0.03 0.12 to 0.057 .48
Service .07 .01
HSCT v radiation oncology 0.58 3.78 to 2.61 .72 0.06 2.48 to 2.35 .96
Medical oncology v radiation oncology 1.91 0.14 to 3.95 .07 1.91 0.61 to 3.22 .004
Work status (not working v other) 2.29 0.18 to 4.40 .03 1.13 0.28 to 2.54 .12
SDS-15 baseline 0.26 0.38 to 0.14  .001 0.44 0.53 to 0.35  .001
Abbreviations: HSCT, hematopoietic stem-cell transplantation; SDS-15, Symptom Distress Scale–15.
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